Access cutting-edge metastatic breast cancer treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access metastatic breast cancer specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related metastatic breast cancer treatment provided free
This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate \[ADP\]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.
Sponsor: Massachusetts General Hospital
Check if you qualify for this metastatic breast cancer clinical trial in Boston, MA
If you're searching for metastatic breast cancer treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.